SAB Biotherapeutics, Inc.
Company Snapshot: SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing immunotherapeutic human antibodies. The company applies advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce human antibodies targeted at specific diseases, including infectious diseases, such as COVID-19 and influenza; immune system disorders, including type 1 diabetes and organ transplantation; and cancer. Its DiversitAb platform is applicable to a range of human diseases. The company was founded in 2014 and is headquartered in Sioux Falls, South Dakota.
- Nov 21 2022 SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
- Nov 15 2022 SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
- Nov 8 2022 SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
- Nov 3 2022 SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference